Head-To-Head Survey: TG Therapeutics (NASDAQ:TGTX) and Kyntra Bio (NASDAQ:KYNB)

Kyntra Bio (NASDAQ:KYNB) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Kyntra Bio and TG Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
TG Therapeutics	55.22%	73.49%	34.14%

Valuation and Earnings

This table compares Kyntra Bio and TG Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44 million	3.50	$183.45 million	$45.30	0.12
TG Therapeutics	$799.54 million	10.41	$447.18 million	$2.74	19.84

TG Therapeutics has higher revenue and earnings than Kyntra Bio. Kyntra Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Kyntra Bio and TG Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2	0	5	0	2.43
TG Therapeutics	1	2	6	0	2.56

Kyntra Bio presently has a consensus target price of $36.80, indicating a potential upside of 560.68%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 15.87%. Given Kyntra Bio’s higher possible upside, research analysts clearly believe Kyntra Bio is more favorable than TG Therapeutics.

Risk & Volatility

Kyntra Bio has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Summary

TG Therapeutics beats Kyntra Bio on 9 of the 13 factors compared between the two stocks.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.